Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Nov 12;25(1):4.
doi: 10.1007/s11892-024-01557-z.

Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials

Feng Chen #  1 , Disheng Zhou #  1 , Alice Pik-Shan Kong  2 , Nga Ting Yim  3 , Siyu Dai  4   5   6 , Yu Nan Chen  7 , Lai Ling Hui  8   9
Affiliations
Meta-Analysis

Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials

Feng Chen et al. Curr Diab Rep. .

Abstract

Purpose of review: Supplementation of nicotinamide mononucleotides (NMN) has been claimed to improve metabolic function. We reviewed human randomised controlled trials (RCTs) of NMN to evaluate its effect on markers of glucose and lipid metabolism.

Recent findings: Eight RCTs on NMN (dosage ranged 250-2000 mg/d for a duration of 14 days to 12 weeks) involving a total of 342 middle-age/older adults (49% females, mainly non-diabetic) reporting at least one outcome on glucose control or lipid profile published in 2021-2023 were reviewed. The random-effects meta-analyses indicated no significant benefit of NMN on fasting glucose, fasting insulin, glycated hemoglobin, homeostatic model assessment for insulin resistance and lipid profile. Based on the small number of RCTs involving mainly relatively healthy adults, short-term supplementation of NMN of 250-2000 mg/d did not show significantly positive impacts on glucose control and lipid profile.

Keywords: Glucose control; Lipid profile; NAD; Nicotinamide mononucleotide; Supplementation.

PubMed Disclaimer

Conflict of interest statement

Declarations Competing Interest One of our co-authors Prof Alice Pik Shan KONG is one of section editors for section entitled "Lifestyle and Team Based Management in People with Cardiovascular Risk" in Current Diabetes Reports. Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

Figures

Fig. 1
Fig. 1
PRISMA diagram
Fig. 2
Fig. 2
Risk of bias assessment in the randomised parallel-arm studies. A. Risk of bias summary. B. Quality assessment percentages of all included studies
Fig. 3
Fig. 3
Forest plot of the effect of NMN supplements on markers of glucose and lipid metabolism
See this image and copyright information in PMC

References

    1. Houtkooper RH, et al. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev. 2010;31(2):194–223. - PMC - PubMed
    1. Bogan KL, Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu Rev Nutr. 2008;28:115–30. - PubMed
    1. Yang F, et al. Association of Human Whole Blood NAD(+) Contents With Aging. Front Endocrinol (Lausanne). 2022;13:829658. - PMC - PubMed
    1. Orlandi I, Alberghina L, Vai M. Nicotinamide, Nicotinamide Riboside and Nicotinic Acid-Emerging Roles in Replicative and Chronological Aging in Yeast. Biomolecules. 2020;10(4):604. - PMC - PubMed
    1. Covarrubias AJ, et al. NAD(+) metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119–41. - PMC - PubMed

MeSH terms